SEC Form SC 13G filed by Pulmonx Corporation

2/9/24 9:49:31 AM ET

Medical/Dental Instruments

Health Care

Get the next $LUNG alert in real time by email

SC 13G 1 filing.txt SCHEDULE 13G Amendment No.0 PULMONX CORP COMMON STOCK Cusip #745848101 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #745848101 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 3,302,590 Item 6: 0 Item 7: 3,309,501 Item 8: 0 Item 9: 3,309,501 Item 11: 8.639% Item 12: HC Cusip #745848101 Item 1: Reporting Person - Abigail P. Johnson Item 2: (a) [ ] (b) [ ] Item 4: United States of America Item 5: 0 Item 6: 0 Item 7: 3,309,501 Item 8: 0 Item 9: 3,309,501 Item 11: 8.639% Item 12: IN Item 1(a). Name of Issuer: PULMONX CORP Item 1(b). Address of Issuer's Principal Executive Offices: 700 CHESAPEAKE DRIVE REDWOOD CITY, CA 94063 US Item 2(a). Name of Person Filing: FMR LLC Item 2(b). Address or Principal Business Office or, if None, Residence: 245 Summer Street, Boston, Massachusetts 02210 Item 2(c). Citizenship: Not applicable Item 2(d). Title of Class of Securities: COMMON STOCK Item 2(e). CUSIP Number: 745848101 Item 3. This statement is filed pursuant to Rule 13d-1(b) or 13d-2(b) or (c) and the person filing, FMR LLC, is a parent holding company in accordance with Section 240.13d-1(b)(1)(ii)(G). (Note: See Exhibit A). Item 4. Ownership (a) Amount Beneficially Owned: 3,309,501 (b) Percent of Class: 8.639% (c) Number of shares as to which such person has: (i) sole power to vote or to direct the vote: Please see the responses to Items 5 and 6 on the cover page (ii) shared power to vote or to direct the vote: 0 (iii) sole power to dispose or to direct the disposition of: 3,309,501 (iv) shared power to dispose or to direct the disposition of: 0 Item 5. Ownership of Five Percent or Less of a Class. Not applicable. Item 6. Ownership of More than Five Percent on Behalf of Another Person. One or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the COMMON STOCK of PULMONX CORP. No one other person's interest in the COMMON STOCK of PULMONX CORP is more than five percent of the total outstanding COMMON STOCK. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. See attached Exhibit A. Item 8. Identification and Classification of Members of the Group. Not applicable. Item 9. Notice of Dissolution of Group. Not applicable. Item 10. Certifications. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. Signature After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. February 8, 2024 Date /s/ Stephanie J. Brown Signature Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. Exhibit A Pursuant to the instructions in Item 7 of Schedule 13G, the following table lists the identity and Item 3 classification, if applicable, of each relevant entity that beneficially owns shares of the security class being reported on this Schedule 13G. Entity ITEM 3 Classification FIAM LLC IA Fidelity Institutional Asset Management Trust Company BK Fidelity Management & Research Company LLC * IA Fidelity Management Trust Company BK * Entity beneficially owns 5% or greater of the outstanding shares of the security class being reported on this Schedule 13G. Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. This filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned, by FMR LLC, certain of its subsidiaries and affiliates, and other companies (collectively, the "FMR Reporters"). This filing does not reflect securities, if any, beneficially owned by certain other companies whose beneficial ownership of securities is disaggregated from that of the FMR Reporters in accordance with Securities and Exchange Commission Release No. 34-39538 (January 12, 1998). RULE 13d-1(k)(1) AGREEMENT The undersigned persons, on February 8, 2024, agree and consent to the joint filing on their behalf of this Schedule 13G in connection with their beneficial ownership of the COMMON STOCK of PULMONX CORP at December 29, 2023. FMR LLC By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* Abigail P. Johnson By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 26, 2023, by and on behalf of Abigail P. Johnson** * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. ** This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 31, 2023, accession number: 0000315066-23-000038.

Get the next $LUNG alert in real time by email

Recent Analyst Ratings for

$LUNG

Date	Price Target	Rating	Analyst
6/4/2024	$12.00	Buy	Lake Street
2/23/2024	$16.00 → $14.00	Overweight → Equal Weight	Wells Fargo
9/5/2023	$18.00	Buy	Craig Hallum
2/27/2023	$10.00 → $15.00	Equal Weight → Overweight	Wells Fargo
1/3/2023	$8.00	Neutral → Underperform	BofA Securities
12/12/2022	$14.00 → $10.00	Neutral → Buy	Citigroup
7/11/2022	$23.00 → $19.00	Buy → Neutral	Citigroup
3/2/2022	$28.00	Neutral	BofA Securities

More analyst ratings

SEC Form SC 13G filed by Pulmonx Corporation

Chat with this insight

Recent Analyst Ratings for $LUNG

$LUNG Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13G/A filed by Pulmonx Corporation (Amendment)

SEC Form SC 13G filed by Pulmonx Corporation

SEC Form SC 13G/A filed by Pulmonx Corporation (Amendment)

$LUNG Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

PRESIDENT AND CEO Williamson Steven S. bought $97,436 worth of shares (14,245 units at $6.84), increasing direct ownership by 7% to 219,531 units (SEC Form 4)

$LUNG SEC Filings

SEC Form 10-Q filed by Pulmonx Corporation

Pulmonx Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

SEC Form 10-Q filed by Pulmonx Corporation

$LUNG Financials

Live finance-specific insights

Pulmonx Reports Third Quarter 2024 Financial Results

Pulmonx to Report Third Quarter 2024 Financial Results on October 30, 2024

Pulmonx Reports Second Quarter 2024 Financial Results

$LUNG Press Releases

Fastest customizable press release news feed in the world

Pulmonx Reports Third Quarter 2024 Financial Results

Pulmonx to Report Third Quarter 2024 Financial Results on October 30, 2024

Pulmonx Announces Presentation of Clinical Data from the AeriSeal® CONVERT Trial and 5-Year Follow-up Data from the LIBERATE Study at the European Respiratory Society Congress 2024

$LUNG Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Lake Street initiated coverage on Pulmonx with a new price target

Pulmonx downgraded by Wells Fargo with a new price target

Craig Hallum initiated coverage on Pulmonx with a new price target

$LUNG Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Director French Glendon E. Iii sold $130,400 worth of shares (20,000 units at $6.52), decreasing direct ownership by 2% to 1,091,974 units (SEC Form 4)

Director French Glendon E. Iii sold $161,800 worth of shares (20,000 units at $8.09), decreasing direct ownership by 2% to 1,111,974 units (SEC Form 4)

CHIEF COMMERCIAL OFFICER Rose Geoffrey Beran sold $30,721 worth of shares (4,586 units at $6.70), decreasing direct ownership by 2% to 295,433 units (SEC Form 4)

$LUNG Market Insights

Live Market Insights

Lake Street Initiates Coverage On Pulmonx with Buy Rating, Announces Price Target of $12

Canaccord Genuity Maintains Buy on Pulmonx, Lowers Price Target to $15

C.H. Robinson Worldwide Posts Upbeat Results, Joins Avis Budget Group, Qualcomm, BorgWarner, Moderna And Other Big Stocks Moving Higher On Thursday

$LUNG Leadership Updates

Live Leadership Updates

Pulmonx Announces Appointment of Mehul Joshi as Chief Financial Officer

Pulmonx Announces Retirement of CEO Glen French and Appointment of Industry Veteran Steve Williamson as President and Chief Executive Officer

The Honest Company Announces Appointment of Michael Barkley, Alissa Hsu Lynch, and Andrea Turner to the Board of Directors

Recent Analyst Ratings for
$LUNG

$LUNG
Large Ownership Changes

$LUNG
Insider Purchases

$LUNG
SEC Filings

$LUNG
Financials

$LUNG
Press Releases

$LUNG
Analyst Ratings

$LUNG
Insider Trading

$LUNG
Market Insights

$LUNG
Leadership Updates